Viking Therapeutics confirmed its global rights to the drug candidate VK2735 and secured manufacturing and supply partnerships with CordenPharma.
8 reports, 3 independent
Updated Sep 24
Mostly repetition
- Reports
- 8
- Developments
- 2
- Repetition
- 75%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Viking Therapeutics confirmed its global rights to the drug candidate VK2735 and secured manufacturing and supply partnerships with CordenPharma.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Viking Therapeutics retains global rights to VK2735 and secured manufacturing support from CordenPharma.1 source
- Viking Therapeutics is developing VK2735, a drug candidate intended for the treatment of obesity, led by CEO Brian Lian.
Keep exploring
The entities involved
-
Viking Therapeutics
company in San Diego, United States
- The weight loss drug market is dominated by major players like Pfizer, Viking Therapeutics, Eli Lilly, and Novo Nordisk, with potential M&A activity and public commentary.
- Major pharmaceutical companies, including Viking Therapeutics, Eli Lilly, and Novo Nordisk, are advancing their weight loss drug pipelines.
Coverage
Newest first; wire copies grouped- fool.com
- themarketsdaily.com
- Insider MonkeyViking Therapeutics Concludes Broad Manufacturing Agreement With CordenPharma To Support Commercialization of VK2735 Viking Therapeutics, Inc. (NASDAQ:VKTX) is among the 11 Best GLP-1 and Weight Loss
- Insider MonkeyH.C. Wainwright Reiterates a Buy Rating on Viking Therapeutics (VKTX), Sets a $102 PT Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the best oversold NASDAQ stocks to buy now. On June 30, H.C. Wa
- Unknown outlet